CoChat
Sign Up
Cited by 57Prostate Cancer Treatment and ResearchRNA Interference and Gene DeliveryDNA and Nucleic Acid Chemistry

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: A novel therapy in prostate cancer

Balaji, K.C., Koul, Hari, Mitra, Sankar, Maramag, Carlos, Reddy, Premveer, Menon, Mani, Kaur Malhotra, Rajwant, Laxmanan, Seethalaksmi·1997·Urology
DOI 10.1016/s0090-4295(97)00390-7
Open this paper in CoChat — free account

Abstract

Objectives To explore the possibility of using antisense oligonucleotide therapy for prostate cancer, we investigated the effect of c-myc-antisense-oligonucleotide (c-myc-As-ODN) in human prostate cancer cell lines such as LNCaP, PC3, and DU145.Methods LNCaP, PC3, and DU145 cells were incubated in the presence of c-myc-As-ODN. Dose (0 to 10 microM) and time dependent (1 to 6 days) effects on proliferation and viability were examined by [3H]thymidine incorporation and MTT assay, respectively. Flow cytometry analysis was carried out to analyze cell cycle status by determining the DNA content in LNCaP cells. Control cultures received either c-myc-sense-ODN or scrambled (nonsense) nucleotides.Results Time- and dose-dependent decreases in DNA synthesis and cell viability were noted for all three prostate cancer cell lines after c-myc-As-ODN treatment. Further studies using LNCaP cells indicated that these changes were accompanied by an increase in the percentage of cells with less than 2N DNA content after c-myc-As-ODN treatment. The results suggest that c-myc-As-ODN induces cell death. Comparison of a c-myc-As-ODN-treated group with a group subjected to isoleucine deprivation revealed that thymidine incorporation was almost the same in c-myc-As-ODN-treated LNCaP cells and in LNCaP cells at early S phase.Conclusions These results suggest that c-myc-As-ODN inhibits prostate cancer cell growth and proliferation mainly by decreasing cell viability.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0090-4295(97)00390-7

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Laxmanan's group verified that c-Myc antisense oligonucleotide induces cell death in LNCaP, PC3, and DU 145 human prostate cancer cell lines by decreasing DNA synthesis and cell viability.

    “As early as 1997, Laxmanan’s group verified c-Myc antisense oligonucleotide (c-Myc-ASO) induces cell death in three kinds of human prostate cancer cell lines, LNCaP, PC3, and DU 145, by decreasing DNA synthesis and cell viability.554”

    From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [554]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Kaighn, 1979, Establishment and characterization of a human prostatic cell line (PC3), Invest Urol, 17, 16
  2. Micky, 1980, Characterization of a human adenocarcinoma cell line (DU145) as a monolayer culture and as a solid tumor in athymic mice, Prog Clin Biol Res, 37, 64

Cited by

Sorted by citations

Related

Metadata

Authors
Balaji, K. C., Koul, H., Mitra, S., Maramag, C., Reddy, P., Menon, M., Kaur Malhotra, R., & Laxmanan, S.
Affiliations
University of Massachusetts Chan Medical School (US)
Corresponding author
Laxmanan, Seethalaksmi
ORCID
Venue
Urology
Publisher
Elsevier BV
Published
1997-12
Volume
50
Issue
6
Pages
1007-1015
ISSN
0090-4295 (ISSN-L)
DOI
10.1016/s0090-4295(97)00390-7
OpenAlex
W1971189823
Cited by
57
References
30
Citations by year
2025: 1 · 2023: 1 · 2022: 1 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 1 · 2016: 3 · 2015: 1 · 2012: 2
FWCI
3.96
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Urology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
Keywords
c-Myc, antisense oligonucleotides, prostate cancer, antiproliferative activity, cell viability, cell cycle, DNA synthesis inhibition, LNCaP cells, PC-3 cells, DU145 cells, isoleucine deprivation, gene therapy
MeSH terms
Analysis of Variance, Autoradiography, Cell Division, Depression, Chemical, Dose-Response Relationship, Drug, Drug Screening Assays, Antitumor, Flow Cytometry, Humans, Male, Prostatic Neoplasms, Time Factors, Tumor Cells, Cultured, Genes, myc, Oligonucleotides, Antisense

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review